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Recently, mRNA vaccines have been introduced as a safety-optimized alternative to plasmid DNA-based vaccines for protection
against allergy. However, it remained unclear whether the short persistence of this vaccine type would limit memory responses and
whether the protective immune response type would be maintained during recurrent exposure to allergen. We tested the duration
of protectivememory responses inmice vaccinated withmRNA encoding the grass pollen allergen Phl p 5 by challenging themwith
recombinant allergen, 3.5, 6, and 9 months after vaccination. In a second experiment, vaccinated mice were repeatedly challenged
monthly with aerosolized allergen over a period of 7 months. Antibody and cytokine responses as well as lung inflammation
and airway hyperresponsiveness were assessed. mRNA vaccination induced robust TH1 memory responses for at least 9 months.
Vaccination efficiently suppressed TH2 cytokines, IgE responses, and lung eosinophilia. Protection was maintained after repeated
exposure to aerosolized allergen and no TH1 associated pathology was observed. Lung function remained improved compared
to nonvaccinated controls. Our data clearly indicate that mRNA vaccination against Phl p 5 induces robust, long-lived memory
responses, which can be recalled by allergen exposure without side effects. mRNA vaccines fulfill the requirements for safe
prophylactic vaccination without the need for booster immunizations.
1. Introduction
Due to a constant rise in incidence of type I allergic diseases
the need for effective treatment options is apparent. However,
specific immunotherapy (SIT), the only treatment currently
available, is time-consuming and entails many disadvantages
such as the potential to create new sensitizations and serious
side effects, including anaphylaxis. Moreover, the inevitable
transition from extract-based SIT to component-resolved
diagnosis and therapy of allergic diseases with recombinant
molecules seems to be a lengthy process. An alternative
concept to SIT with recombinant molecules includes DNA
immunization with allergen genes, an approach whichmean-
while has entered the clinical study phase [1–3].
In the past years, the urgent need to fight the worldwide
increasing incidence of allergies also drew attention to “true
vaccination” against allergic diseases, that is, prophylactic
immunization of healthy individuals [4, 5].The identification
of children at high risk to develop allergy has improved
significantly [6, 7], thus facilitating the selection of target
groups for prophylactic interventions. However, allergen
extracts licensed for treatment of established allergies will
not be applicable for prophylactic immunization due to safety
issues and the risk to induce de novo sensitizations [8–
10]. Only modified (hypoallergenic) allergen derivatives and
gene vaccines can be considered as suitable candidates for
prophylactic allergy vaccines. Among gene vaccines, mRNA
conforms best to the stringent requirements for vaccines
against type I allergy. Due to its short in vivo persistence
mRNA acts in an “immunize and disappear” way, thus
limiting expression of encoded allergens [11]. Furthermore,
and in contrast to DNA vaccines, mRNA vaccines lack
control sequences and cannot integrate into the host genome.
These properties led to the classification of non-replicative
mRNA as non-gene therapy by regulatory authorities [12].
Application of mRNA has so far proven its effectiveness
for vaccination against infectious diseases and tumors in
animal models [13, 14] and also in clinical studies with
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mRNA encoding tumor-associated antigens [15, 16]. With
regard to type I allergies we have demonstrated that mRNA
vaccines induce a protective TH1-type response against a
panel of different allergens, leading to inhibition of specific
IgE production and prevention of lung inflammation and
airway hyperresponsiveness (AHR) in mice [17]. Despite the
proof that mRNA vaccines are effective and protect against
allergic sensitization in murine models, doubts about their
long-term efficacy remained. There have been concerns that
short-term antigen expression might result in weak memory
responses unable to protect from future encounters [18].
Therefore, in the present paper, one set of experiments
investigates the long-term protection after mRNA vacci-
nation (up to nine months after vaccination). A second
approach deals with the robustness of the protective response.
The immune system of patients under real-life conditions is
exposed to allergen repetitively over weeks and months, or
even perennial, depending on the allergen.This is in contrast
to typical experimental setups which usually perform a few
allergen challenges within a short time period. Hence we
simulated the human situation of seasonal pollen exposure
by a repeated challenge of vaccinated mice with aerosolized
grass pollen allergen (up to seven months after vaccination).
2. Materials and Methods
2.1. Preparation of mRNA Vaccines. The plasmid encoding
Phl p 5, pTNT-P5, has been described [17]. Plasmids for RNA
transcription were purified using an EndoFree Plasmid Giga
Kit (Qiagen, Du¨sseldorf, Germany). For RNA transcription,
plasmids were linearized and templates were purified via
phenol-chloroform-isoamyl alcohol extraction, followed by a
single chloroform-isoamyl alcohol extraction. Plasmids were
precipitated by adding a 1/10 volume of 3M sodium acetate
(pH 5.2) and two volumes of 100% ethanol on ice and washed
three times with 70% ethanol. All transcription reactions
were performed with T7 or SP6 RiboMAX Large Scale
RNA Production Systems (Promega, Mannheim, Germany).
Residual template DNA was removed by means of digestion
with RNAse-free DNAse (Promega, Mannheim, Germany).
After transcription, the RNA was precipitated by ammonium
acetate precipitation (addition of 1 volume 5M ammonium
acetate, 15min on ice) followed by centrifugation, washed
with 70% ethanol, and resuspended in nuclease-free H
2
O.
Capping was performed in vitro by using a ScriptCap m7G
Capping Kit (Epicentre Biotechnologies, Madison, USA),
following the manufacturer’s instructions.
2.2.Animals and Immunizations. BALB/cmice, aged between
6 and 14 weeks, were obtained from Charles River Laborato-
ries (Sulzfeld, Germany) and were maintained according to
the local guidelines for animal care. All animal experiments
were approved by the Austrian Ministry of Science.
To evaluate the duration of the protective effect of
mRNA immunization, 5 mice per group were immunized
intradermally (i.d.) three times in one-week intervals with
100 𝜇g of capped-Phl p 5mRNA.Non-vaccinatedmice served
as a control group. 3.5, 6, or 9 months after vaccination the
animals were sensitized by two subcutaneous (s.c.) injections
of 200𝜇L PBS containing 1 𝜇g recombinant Phl p 5 (Biomay,
Vienna, Austria) and 100 𝜇LAlu-Gel-S (1.3% suspension with
an aluminium content of 5.9–7.1mg/mL, Serva Electrophore-
sis GmbH, Heidelberg, Germany) in a 10-day interval. Seven
days after the second sensitization, mice were exposed to
nebulized recombinant Phl p 5 in PBS for 30min on three
consecutive days.Therefore, 5mL recombinant Phl p 5 in PBS
(0.2mg/mL) was nebulized using a PARI BOY SX nebulizer
with a PARI LL nebulizer head (PARI, Starnberg, Germany)
in a 25 × 25 × 25 cm nebulization chamber.
To analyze the effect of repeated allergen challenge, 5 ani-
mals per group were vaccinated i.d. three times in one-week
intervals, with either 100 𝜇g of capped-Phl p 5 or capped-Bet
v 1 control (mock) mRNA (encoding the irrelevant allergen
Bet v 1). Non-vaccinated mice served as a control group. All
groups were sensitized twice by s.c. injection of 200𝜇L PBS
containing 1 𝜇g rPhl p 5 and 100 𝜇L Alu-Gel-S 33 and 42
days after the last vaccination. Seven days after the second
sensitization, the mice were challenged three times with
1mg nebulized rPhl p 5 in PBS. On the next day, Penh was
measured to assess AHR. These challenges were repeated
monthly over a period of seven months. Sera were collected
at regular intervals during the course of the experiments.
2.3. Serology: ELISA and Mediator Release Assay. Antigen-
specific IgG1 and IgG2a antibody levels in sera were deter-
mined by using a luminescence-based ELISA, as described
[19]. Sera were diluted 1 : 100,000 for IgG1 and 1 : 10,000 for
IgG2a determination. Functional IgE levels were assessed by
using a rat basophil leukemia (RBL) cell release assay as
described previously [20]. For the determination of IgE levels,
sera were diluted 1 : 100 (Figure 1) or 1 : 150 (Figure 4).
2.4. Lymphocyte Cultures and Cytokine Detection. To deter-
mine cytokine secretion by splenocytes, spleens were isolated
and single cell suspensions were prepared as described [19].
Cells were restimulated in vitro in the absence or presence of
10 𝜇g/mL recombinant Phl p 5 for 48 h. Cytokine expression
in the culture supernatants was analyzed with a FlowCytomix
Kit (eBioscience, Schwechat, Austria), following the manu-
facturer’s instructions.
2.5. Bronchoalveolar Lavage. Bronchoalveolar lavage (BAL)
was performed as described [21]. In short, cytokines were
determined by FlowCytomix assay and cells were stained
for FACS analysis with the following markers: anti-CD19-
PE/Cy7, anti-CD45-PerCP/Cy5.5, anti-CD4-APC/Cy7, anti-
Gr1-APC (all BioLegend, London, UK), anti-CD8-FITC
(eBioscience, Schwechat, Austria), and anti-CD25-PE (BD
Biosciences, Schwechat, Austria). Red blood cells were lysed
and cells were analyzed on a FACSCanto II flow cytometer
(BD Biosciences, San Jose, CA). The eosinophil population
was distinguished by CD45medGr1lowside-scatterhigh pheno-
type. Neutrophils were identified as a CD45high, Gr1high cell
population.
2.6. Whole-Body Plethysmography. To measure the overall
airway obstruction, non-invasive unrestrained whole-body
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Figure 1: Phl p 5-specific IgG1 (a), IgG2a (b), and IgE (c) antibodies one week after sensitization. BALB/c mice were prevaccinated or left
untreated and sensitized with recombinant Phl p 5 after the indicated time interval. Data are shown as relative light units of a luminometric
ELISA or as percentage of total release induced by addition of 10%Triton X-100 and presented asmeans ± SEM (𝑛 = 5). ∗𝑝 < 0.05; ∗∗𝑝 < 0.01.
plethysmography (WBP) was performed using a Buxo WBP
system consisting of a Bias Flow Regulator, 6WBP chambers,
a MAX II preamplifier unit, and BioSystem XA Software
(Buxco, Winchester, UK).The animals were put into individ-
ual chambers and exposed to nebulized 0.9% NaCl followed
by increasing concentrations of nebulized methacholine
(5mg/mL; 10mg/mL dissolved in 0.9% NaCl) followed by
0.9% NaCl for a recovery phase. 50 𝜇L of methacholine or
NaCl per chamber was applied to the nebulizer head and
enhanced pause in breathing (Penh) was measured for 5min
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at each concentration. Data were analyzed as the area under
the curve [22].
2.7. Dynamic Lung Resistance and Compliance Measurement.
Resistance and dynamic compliance were measured with a
FinePointe Series RC site (Buxco,Winchester,UK), according
to the manufacturer’s instructions. Mice were anesthetized
by means of intraperitoneal ketamine/xylazine injection, and
the trachea was surgically exposed, cannulated, and con-
nected to the ventilator. Transpulmonary pressure was mea-
sured by inserting an esophageal cannula. Baseline signals
for resistance and dynamic compliance were recorded, and
mice were exposed to aerosolized PBS containing increasing
amounts of methacholine (5mg/mL; 10mg/mL). Values for
each dose are expressed as raw values or percentage of
baseline values.
2.8. Statistical Analysis. Differences between means of vac-
cinated versus control sample groups were analyzed by
unpaired 𝑡-test (Figures 1–3). Comparisons between multiple
groups (Figures 5 and 6) were done by one-way ANOVA
followed by Tukey’s post hoc test. All statistical analyses were
performed using GraphPad Prism 5.
3. Results
3.1. RNA Vaccination Induces Long-Term Protective Memory
Responses. To evaluate the long-term memory and duration
of the protective effect after mRNA immunization, animals
were vaccinated three times in one-week intervals with 100𝜇g
of capped-Phl p 5mRNA i.d. and sensitizedwith recombinant
allergen after 3.5, 6, and 9 months, respectively. Sensitization
was performed by s.c. injection of 1𝜇g recombinant Phl p
5 in alum. Seven days later, mice received three challenges
with nebulized recombinant Phl p 5, on three consecutive
days, in order to induce TH2-mediated lung inflammation.
The effect of mRNA vaccination on the humoral immune
response was determined by measuring IgG1 and IgG2a
levels after the last aerosol challenge. We found antigen-
specific IgG1 significantly elevated in prevaccinated mice
compared to control animals even 9 months after the initial
vaccination (Figure 1(a)), suggesting the presence of B cell
memory. More strikingly, only prevaccinated mice showed
Phl p 5-specific IgG2a, indicating the maintenance of an
RNA vaccine-induced TH1 memory for at least 9 months
(Figure 1(b)). Levels of functional Phl p 5-specific IgE were
assessed by RBL release assay and data shows that mRNA
vaccination reduced allergen-specific IgE levels at all three
time points (Figure 1(c)). This data clearly demonstrates that
RNA vaccination induces a long-lasting humoral immune
response and maintains a TH1-biased memory, which pre-
vents IgE induction for at least 6 months following prophy-
lactic immunization.
To evaluate the long-term effects of mRNA vaccination
on T cell responses, splenocytes of prevaccinated and control
animals were harvested at each time point and cytokine
secretion upon restimulation with antigen was measured.
In contrast to cells from prevaccinated mice, splenocytes
from control animals displayed elevated secretion of TH2
cytokines, including IL-5, IL-6, and IL-13 (Figures 2(a)–
2(c)). In return, prevaccination significantly increased the
expression of the TH1-type cytokines IL-2 and IFN-𝛾 even
9 months after vaccination, compared to cells from con-
trol mice (Figures 2(d)-2(e)). This data confirms that RNA
vaccine-induced TH1 memory responses are robust and
long-lasting. No significant differences in IL-10 expression
could be detected between prevaccinated and control groups
(Figure 2(f)). IL-17 production was below the detection limit,
whereas levels of IL-21 and IL-22 were detectable but not
influenced by vaccination (data not shown).
Exposure to inhalant allergens, such as the grass pollen
allergen Phl p 5, can cause the emergence of inflammation in
the lung and the development of asthma. To test the efficacy
of mRNA vaccination to protect from lung inflammation,
BAL fluids were analyzed. The levels of IFN-𝛾 were found
to be significantly higher in the BAL fluids of prevaccinated
mice (Figure 3(d)) and correlatedwith reduced levels of TH2-
type cytokines. BAL fluids of prevaccinated mice contained
less IL-4, IL-5, and IL-13 (Figures 3(a)–3(c)) compared to
control groups. Eosinophil recruitment, one of the hallmarks
of allergic lung inflammation, could be measured in all
groups after the challenge with aerosolized allergen but was
significantly reduced in prevaccinated mice (Figure 3(e)),
whereas the percentage of infiltrating neutrophils in the lung
was increased in the vaccinated groups (Figure 3(f)).
An important characteristic of allergic asthma is
increasedAHR.We assessed the effects ofmRNA vaccination
on AHR by measuring resistance and dynamic compliance
in response to increasing concentrations of aerosolized
methacholine. No statistically significant differences
between prevaccinated and control mice could be detected,
concerning neither resistance nor compliance of the lungs.
However, by trend, vaccinated groups showed reduced
resistance and increased compliance. This also indicates
that the increase in neutrophils during the acute phase had
no detrimental effect on lung function (Supplementary
Figure S1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2015/797421).
3.2. RNA Vaccination Maintains Long-Term Protection over
Repeated Aerosol Challenges. To determine the robustness
of the protective immune response and whether repeated
aerosol exposure would either abrogate the TH1-mediated
protective effect by reconversion to an allergic TH-2 response
or induce TH1-driven side effects, BALB/c mice were pre-
vaccinated with an mRNA vaccine encoding Phl p 5 or
the irrelevant antigen Bet v 1 (mock control) and sensitized
with recombinant Phl p 5 one month later. Subsequently,
mice were challenged monthly by exposure to aerosolized
recombinant Phl p 5 on three consecutive days over a period
of seven months. IgG1 and IgG2a levels were determined by
ELISA after each challenge with aerosolized allergen.
Elevated levels of antigen-specific IgG2a were present in
sera from prevaccinated mice throughout the experiment,
indicating the maintenance of TH1-type memory induced
by mRNA vaccination (Figure 4(b)). Prevaccinated mice also
showed higher Phl p 5-specific IgG2a titers compared to the
mock-RNA control groups, clearly pointing to the specificity
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Figure 2: Levels of IL-5 (a), IL-6 (b), IL-13 (c), IL-2 (d), IFN-𝛾 (e), and IL-10 (f) were determined in culture supernatants after in vitro
restimulation of splenocytes with rPhl p 5. Data are displayed as means ± SEM (𝑛 = 5). ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
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Figure 3: Levels of IL-4 (a), IL-5 (b), IL-13 (c), and IFN-𝛾 (d) as well as the percentage of eosinophils (e) and neutrophils (f) of total leukocytes
in BAL fluids were assessed. Data are shown as means ± SEM (𝑛 = 5). ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
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Figure 4: Time course of Phl p 5-specific IgG1 (a), IgG2a (b), and IgE (c) antibody levels as measured by a luminometric ELISA or RBL assay,
respectively. BALB/c mice were prevaccinated and sensitized one month later, followed by monthly exposure to aerosolized rPhl p 5. Data are
displayed as means ± SEM (𝑛 = 5).
of the mRNA vaccination. Phl p 5-specific IgG1 antibodies
did not differ between the groups (Figure 4(a)). Importantly,
vaccination with mRNA strongly suppressed the induction
of Phl p 5-specific IgE antibodies. Levels of IgE were signifi-
cantly reduced in the prevaccinated group even aftermice had
been challenged 21 times with aerosolized recombinant Phl p
5 over a period of sevenmonths (Figure 4(c)).This correlated
with significantly reduced secretion of TH2 cytokines IL-
5, IL-6, and IL-13 by splenocytes from prevaccinated mice,
which had been restimulated in vitro (Figures 5(a)–5(c)). In
contrast, IL-2 and IFN-𝛾 were increased in prevaccinated
mice (Figures 5(d)-5(e)), indicating the maintenance of a
TH1-biased response. We further confirmed that vaccination
does not induce Tr1 cells, as shown by similar levels of IL-10
secretion in all groups (Figure 5(f)).
In addition to the systemic immune response, we also
investigated the response in the target organ of the aerosol
challenge, the lung. Similar to the cytokine expression by in
vitro stimulated splenocytes, levels of IFN-𝛾 were higher in
BAL fluids from prevaccinated mice (Figure 6(b)), and this
IFN-𝛾 induction correlated with reduced IL-5 secretion, as
prevaccinated mice had significantly decreased IL-5 levels
in BAL fluids compared to control groups (Figure 6(a)).
Furthermore, antigen specificity of protection was con-
firmed as levels of IFN-𝛾 and IL-5 expression in mock-
RNA vaccinated groups were similar to the control group
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Figure 5: Levels of IL-5 (a), IL-6 (b), IL-13 (c), IL-2 (d), IFN-𝛾 (e), and IL-10 (f) in supernatants of in vitro restimulated splenocyte cultures.
Cells were obtained frommice immunized 9 months before, sensitized, and repeatedly exposed to aerosolized rPhl p 5. Data are displayed as
means ± SEM (𝑛 = 5). ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
(Figures 6(a) and 6(b)). As seen in the acute phase response
(Figure 3), the percentage of eosinophils infiltrating into the
lung was significantly reduced in prevaccinated mice despite
repeated aerosol challenges (Figure 6(c)). The percentage of
neutrophils in the lung infiltrate was relatively high.However,
this increased infiltration of neutrophils was not dependent
on prevaccination andwas present in all groups (Figure 6(d)).
To assess AHR during the course of this experiment we
measured enhanced pause (Penh) with noninvasive whole-
body plethysmography. Mice pretreated with the mRNA
vaccine overall showed lower AHR compared to mock-
RNA treated or control animals (Figure 6(e)). Additionally,
after the final airway challenge, AHR was directly assessed
using invasive R/C measurement. In agreement with the
immunological results, these data also indicate a protective
effect of the prevaccination with mRNA, which improved
lung function compared to the nonvaccinated group (Figures
6(f) and 6(g)).
4. Discussion
We have previously demonstrated that mRNA vaccination
can protect against a broad range of allergens in a mouse
model of allergic asthma [17]. However, concerns have been
raised that the short persistence of mRNA vaccines might
induce insufficient memory responses. In the current study,
we show for the first time that the protective, antiallergic
TH1 memory is long-lasting and sufficient to prevent allergic
sensitization up to 9 months after the initial vaccination.
Sensitization, that is, induction of a TH2-biased immune
response, is inhibited with respect to both branches of
the immune system. Vaccination with mRNA encoding the
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Figure 6: Levels of IL-5 (a) and IFN-𝛾 (b) as well as the percentage of eosinophils (c) and neutrophils (d) of total leukocytes in BAL
fluids determined 9 months after mRNA immunization. Effects of prevaccination on lung function were determined by measuring airway
hyperresponsiveness via noninvasivewhole-body plethysmography throughout the experiment (e) or invasivemeasurement of lung resistance
(f) and dynamic compliance (g) at the endpoint. Mice were exposed to nebulized 0.9% NaCl followed by increasing concentrations of
nebulized methacholine. Data are shown as means ± SEM (𝑛 = 5). ∗𝑝 < 0.05.
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grass pollen allergen prevents expression of TH2 cytokines,
such as IL-5 and IL-13, and proinflammatory IL-6 by in
vitro restimulated splenocytes, thus reflecting the systemic
effect. It also inhibits the induction of a TH2-mediated lung
inflammation as indicated by reduction of TH2 cytokines
in the lung. IFN-𝛾 in BAL fluid was elevated in vaccinated
mice, especially in the acute phase of the response. IFN-
𝛾 plays an ambiguous role in allergic lung inflammation.
On the one hand, it directly inhibits TH2 cells, induces
apoptosis in eosinophils, reduces levels of lung IgE and airway
hyperresponsiveness, and directly acts on lung epithelial cells,
thus blockingmucus production [23–25]. On the other hand,
chronic expression of IFN-𝛾 has also been shown to enhance
allergen induced eosinophilia, IL-5, and IL-13 expression [24]
and has induced side effects when administered to allergic
patients [25]. These data illustrate that IFN-𝛾 has potent
immunomodulatory capacities that can be highly beneficial
but also induce side effects at high dosages. In our model, no
detrimental effects were observed.
The induction of regulatory T cells has been shown to
play an important role in keeping or restoring a nonallergic
balanced status of the immune system against allergens [26].
However, in our model no significant differences in IL-10
expression could be detected between prevaccinated and
control groups indicating no crucial role of IL-10-secreting
Treg cells (Tr1) in the mechanisms underlying protection
from an allergic immune response by mRNA immunization
(Figure 2(f)).
Furthermore, recruitment of eosinophils to the lung was
significantly reduced in the vaccination groups. Interestingly,
the percentage of infiltrating neutrophils in the lung was
increased in the vaccinated group during the acute phase
of the lung response (Figure 3(f)). Similarly, Duechs et al.
observed that application of various TLR agonists in an
asthma model reduced airway eosinophilia and airway resis-
tance but at the same time increased neutrophil influx [27].
It has been shown that IL-17 derived from TH17 cells [28] or
iNKT cells [29] can induce recruitment of neutrophils to the
lung. TH17 cells have also recently been found to be involved
in the pathology of allergy [30]. However, in our model IL-
17 production was below the detection limit, whereas levels
of IL-21 and IL-22 were detectable but no alterations could
be seen in the vaccination groups (data not shown). IFN-
𝛾 has also been shown to boost trafficking of neutrophils
into the lung [31], and the elevated levels of this cytokine
during the acute phase in the vaccinated groupsmay therefore
contribute to the enhanced influx of neutrophils. During the
chronic phase of inflammation, due to repeated exposure
to aerosolized allergen, the percentage of neutrophils in the
lung infiltrate was relatively high. However, this increased
infiltration of neutrophils was not dependent on prevacci-
nation but was present in all groups (Figure 6(d)). TNF-𝛼, a
cytokine secreted by TH1 cells, may also be responsible for
recruitment of eosinophils to the lung [32]. In the acute phase
of the response we found low levels of TNF-𝛼 in splenocytes
which were higher in vaccinated mice compared to control
animals, at least at the earlier challenge time points (Supple-
mentary Figure S2A). TNF-𝛼 levels were higher after chronic
allergen exposure in all groups (Supplementary Figure S2B).
Neutrophil invasion thereforemost likely represents a general
side effect of chronic exposure to allergen and is only induced
by mRNA vaccination during the acute sensitization phase.
Nevertheless, it must be emphasized that even in the acute
phase this vaccine-induced influx of neutrophils does not
impair lung function, as AHR is not increased in these
groups.
Our data further ascertained that mRNA vaccination
induces a robust protection and inhibits induction of a TH2-
type response even after repeated exposure to a high dose of
allergen. Thus, repeated allergen exposure during the pollen
season does neither lead to mitigation of the established
TH1-biased response nor does it induce TH1-driven lung
pathology. In contrast, it acts like booster immunizations and
thus resembles the mechanisms by which lifelong specific
immunity can be maintained against certain pathogens, after
a single vaccination. Likewise one or two injections of an
mRNA vaccine would be sufficient to trigger the allergen-
specific recruitment of protective TH1 memory cells and, in
the case of seasonal allergens, the natural exposure acts as
boost and refreshment of the protective response type. More-
over, prophylactic mRNA vaccination against allergens does
not need as strong immune responses as classical vaccination
approaches against pathogens or tumors. An almost nonde-
tectable primary immune response induced by the mRNA
vaccine is sufficient to set an immunological bias, which pre-
vents subsequent sensitization against the allergen [17, 21, 33].
5. Conclusions
mRNA vaccination prevents an allergen-specific TH2-type
response by suppressing TH2 cytokines, eosinophils, and IgE
expression, while increasing TH1-type parameters such as
IFN-𝛾 expression. Collectively, our data indicate that mRNA
vaccines are effective in inducing a protective, robust, and
long-lasting TH1-biased immune response.
mRNAvaccines therefore combine effective prevention of
allergic sensitization with a commendable safety profile.
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